What is the Hikal PE ratio today?
Hikal's PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹33.8 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹2,524 crore at ₹204.40 a share.
What is the Hikal PB ratio (price to book value)?
Hikal's price-to-book (PB) ratio is 2.11 at the 29 October 2026 close: a market capitalisation of ₹2,524 crore divided by shareholders' equity (book value) of ₹1,199 crore on 31 March 2026. That is a book value of ₹97.07 per share against a share price of ₹204.40.
What is the Hikal net worth?
Hikal's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,199 crore on 31 March 2026, down 5.0% from ₹1,262 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,524 crore at the 29 October 2026 close.
What is the Hikal market cap?
Hikal's market capitalisation was ₹2,524 crore at the 29 October 2026 close: 12.35 crore shares at ₹204.40 each.
What is the Hikal debt to equity ratio?
Hikal's debt-to-equity ratio was 0.57 on 31 March 2026: borrowings of ₹681 crore against total equity of ₹1,199 crore. A year earlier, on 31 March 2025, it was 0.60.
What is the Hikal EPS?
Hikal's basic earnings per share (EPS) were −₹3.96 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹2.74.
Is Hikal debt free?
No. Hikal had borrowings of ₹681 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.57. Its cash and current investments were ₹13.8 crore, so its net debt was ₹667 crore.
What is the Hikal dividend in 2026 and its record date?
In 2026, Hikal has declared two dividends totalling ₹0.60 a share: ₹0.20 (interim) with record date 17 February 2026 and ₹0.40 with record date 4 September 2026.
What is the Hikal promoter holding?
Promoters held 68.85% of Hikal on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Hikal ROE and ROCE?
In FY26, Hikal's return on equity (ROE) was −4.0% and its return on capital employed (ROCE) was 3.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 7.4% and ROCE 11.2%.
What is the Hikal shareholding pattern?
On 30 September 2026, Hikal's shares were held by promoters 68.85%, foreign portfolio investors (FII/FPI) 1.27%, domestic institutions (DII) 5.32% (including mutual funds at 5.09%) and retail and other non-institutional investors 24.56%. Over the year, FII holding was down 2.96 percentage points from 4.23% and DII holding was up 0.16 percentage points from 5.16%.
How does Hikal compare with its peers?
On FY26 consolidated figures, against Panacea Biotec, Dishman Carbogen Amcis and Sai Parenterals: Hikal's operating margin of 3.3% is the third highest of the four (Panacea Biotec −5.9%, Dishman Carbogen Amcis 7.7%, Sai Parenterals 5.7%; peer average 2.5%); its return on equity of −4.0% is the lowest of the four (Panacea Biotec −0.6%, Dishman Carbogen Amcis 1.6%, Sai Parenterals 2.9%; peer average 1.3%).
What is the Hikal book value per share?
Hikal's book value per share was ₹97.07 on 31 March 2026: shareholders' equity of ₹1,199 crore divided by the 12.35 crore shares in issue, down 5.0% from ₹102.21 a year earlier. The share price at the 29 October 2026 close was ₹204.40.
What is the Hikal dividend yield?
Hikal's dividend yield is 0.29% at the 29 October 2026 close: dividends of ₹0.60 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹204.40. They were ₹0.40 on 4 September 2026 and ₹0.20 on 17 February 2026 (interim).
What are the Hikal latest quarterly results?
Hikal's latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net loss ₹7.4 crore, narrower than the loss of ₹22.4 crore in Q1 FY26; revenue from operations ₹403 crore, up 5.9% year on year.
What is the Hikal free cash flow?
In FY26, Hikal generated ₹302 crore of cash from operations and spent ₹148 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹154 crore. In FY25 it was ₹143 crore.
What is the Hikal revenue and profit in FY26?
In FY26 (April 2025–March 2026), Hikal's consolidated net loss was ₹48.8 crore, against a profit of ₹90.8 crore in FY25, on revenue from operations of ₹1,713 crore (down 7.9%).
When are the Hikal next results?
Hikal will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.
Hikal vs Panacea Biotec: how do they compare?
In FY26, Hikal earned net profit of ₹48.8 crore on revenue of ₹1,713 crore, against ₹5.4 crore on ₹640 crore for Panacea Biotec. Hikal's operating margin was 3.3% (Panacea Biotec −5.9%) and its return on equity −4.0% (Panacea Biotec −0.6%). At the 29 October 2026 close, Hikal's market capitalisation was ₹2,524 crore against ₹1,998 crore for Panacea Biotec.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
